Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population‐based study in the Netherlands, 1996–2020
Lina van der Straten(Erasmus MC), Avinash G. Dinmohamed(Netherlands Comprehensive Cancer Organisation), Eduardus F. M. Posthuma(Leiden University Medical Center), Manette A. W. Dinnessen(Netherlands Comprehensive Cancer Organisation), Otto Visser(Netherlands Comprehensive Cancer Organisation), Arnon P. Kater(Amsterdam University Medical Centers), Mark‐David Levin(Albert Schweitzer Hospital), A. W. Langerak(Erasmus MC), Jeanette K. Doorduijn(Erasmus MC Cancer Institute)
Cited by 3
Related Papers
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568